Advertisements

Disopyramide Phosphate Actavis

Quick links to important sections

Disopyramide Phosphate Actavis

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Disopyramide Phosphate Actavis

Quick Facts: Disopyramide Phosphate

Property Description
Active ingredient Disopyramide
Form Oral capsules (Immediate and Extended Release)
Pharmacological class Class Ia Antiarrhythmic Agent
Common use Stabilizing irregular heart rhythms (cardiac arrhythmias)
Origin Synthetic

Disopyramide Phosphate Actavis: What Type of Medicine is It?

Disopyramide Phosphate Actavis is a highly specialized, prescription-only medication. Its active component, Disopyramide, formally classifies it as an antiarrhythmic agent, belonging specifically to the Class Ia antiarrhythmic drug subgroup. This classification reflects the drug's specialized role in managing the electrical activity of the heart. The medication is of synthetic origin and is prepared as the salt disopyramide phosphate for stability, typically administered via the oral route in capsule form.


Composition and Core Function

The medication is a single-ingredient product featuring Disopyramide Phosphate, functioning as a membrane-stabilizing agent within cardiac cells. This principle means the medication’s core purpose is to regulate the heart’s essential electrical cycle. In this capacity, the drug's use is targeted at patients experiencing serious rhythm irregularities, including the maintenance of sinus rhythm in patients with atrial fibrillation. The medicine helps the heart keep a steady, regulated beat, providing an approach for controlling cardiac arrhythmias.


How Does Class Ia Antiarrhythmic Activity Help the Heart?

The significance of the Class Ia antiarrhythmic designation is related to its ability to modulate the flow of electrical impulses necessary for each heartbeat. The drug works by influencing the heart's electrical channels, which slows down the speed of signal transmission across the cardiac tissue. This necessary modulation helps the heart maintain a coordinated and stable rhythm. By preventing the disorganized electrical activity that can trigger serious instabilities, the drug supports the heart's overall function of effective pumping. This action is essential for managing ventricular arrhythmias and certain supraventricular tachycardias.

Regulatory References

  1. Disopyramide: MedlinePlus Drug Information
  2. DISOPYRAMIDE PHOSPHATE capsule Labeling
Advertisements

What side effects are possible with Disopyramide Phosphate Actavis?

Possible Side Effects and Safety Information

The safety profile of Disopyramide Phosphate Actavis is officially documented across several categories, primarily reflecting its anticholinergic and Class Ia antiarrhythmic activity. Adverse reactions are classified by frequency and by the system-organ class affected, based on regulatory standards.


Key Adverse Reaction Categories

Classification Examples of Documented Effects
Very Common (ge 10%) Dry mouth, urinary hesitancy or retention
Common (ge 1% to <10%) Constipation, blurred vision, dizziness, headache, general fatigue, hypotension

The most frequent adverse events are associated with the drug's anticholinergic properties, affecting the Gastrointestinal and Genitourinary systems. Other affected organ classes include Cardiac disorders and the Nervous system.


Serious Adverse Reactions

The most critical documented safety concerns are related to the heart's electrical system and function. These serious adverse reactions include Proarrhythmia, which is the potential for the medicine to induce new or worsen existing heart rhythm problems (such as Torsade de Pointes). Other documented serious events are the Worsening or Precipitation of Congestive Heart Failure (CHF), Severe Hypotension, Acute Urinary Retention, and episodes of Severe Hypoglycemia.


Population-Specific Safety Constraints

Official regulatory documents note that specific populations require specialized safety considerations. Older adults and patients with impaired renal or hepatic function are at a heightened risk for severe anticholinergic effects and hypoglycemia due to changes in drug clearance. Furthermore, close and regular monitoring of the Electrocardiogram (ECG) is a required safety element to detect signs of cardiotoxicity, such as significant widening of the QRS complex.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

Overdosage with Disopyramide Phosphate is documented in official prescribing information as leading to severe and potentially life-threatening cardiac and systemic effects. Documented clinical manifestations primarily involve profound electrical disturbances, including excessive widening of the QRS complex and prolongation of the Q-T interval on the electrocardiogram (ECG).

These electrical changes can quickly lead to severe rhythm disorders such as Ventricular Fibrillation, Torsade de Pointes, and Asystole. Systemic signs of overdose may include severe hypotension, worsening of congestive heart failure, apnea (cessation of breathing), and loss of consciousness.

The regulatory guidance mandates that prompt and vigorous treatment be sought immediately, as such intervention is deemed life-saving. Urgent medical attention is required for any signs of overdosage, especially if the victim has collapsed or is experiencing breathing difficulties.

Management relies entirely on symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. Officially described supportive measures may include gastrointestinal decontamination (e.g., activated charcoal or gastric lavage) and specific circulatory support using intravenous agents like dopamine or isoproterenol. Continuous ECG monitoring in a hospital setting is essential to track specific conduction parameters. Careful monitoring is also noted for patients with impaired renal or hepatic function.

Advertisements

Therapeutic Uses of Disopyramide Phosphate Actavis

What Disopyramide Phosphate Actavis treats: main uses and benefits

Disopyramide is used in the treatment to address certain serious heart rhythm problems. The medication is indicated for documented ventricular arrhythmias that are serious or challenging to manage.

The medicine is commonly applied across conditions characterized by periods of heightened symptoms, helping to ease symptoms related to heightened physiological activity such as severe palpitations, heart pounding, lightheadedness, dizziness, and fainting spells. It is generally used during phases when symptoms become more noticeable, offering symptomatic support that helps patients cope more steadily.

“The medication may contribute to providing rhythm support that may assist in supporting functional stability and contribute to improved comfort during symptomatic periods.”

By helping to stabilize the heart's rhythm, Disopyramide provides support that helps ease the overall symptom burden. It is applied when additional symptomatic assistance is needed to manage the likelihood of severe or recurrent episodes.

Quick Fact: Relief for Severe Palpitations and Dizziness

Regulatory References

  1. DailyMed/FDA label for Disopyramide Phosphate Capsules
Advertisements

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Disopyramide Phosphate Actavis?

Disopyramide Phosphate Actavis is officially indicated for adults with documented, life-threatening ventricular arrhythmias. Eligibility is strictly defined by regulatory labels that list specific populations who must not use the medicine and those requiring restricted use.

Contraindicated Populations

Use is contraindicated in patients with pre-existing conditions, including cardiogenic shock, uncompensated congestive heart failure, or an unpaced second- or third-degree atrioventricular (AV) block. The medicine is also prohibited for individuals with congenital Q-T prolongation or known hypersensitivity to the drug.

Restricted or Limited Use

Use is restricted and requires dosage adjustment for patients with renal (kidney) impairment or hepatic (liver) impairment due to the drug's elimination profile. For the pediatric population (under 18 years), safety and efficacy are often noted as not established. Use in older adults requires caution. The medicine is generally not recommended during pregnancy or breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Disopyramide Phosphate is defined by documented interactions that pose a risk for altered drug exposure or severe additive cardiac effects. Contraindicated combinations include other Class I and Class III antiarrhythmic agents and certain medicinal products that can provoke Torsade de pointes, such as specific macrolide antibiotics (e.g., erythromycin, clarithromycin) and tricyclic antidepressants. Co-administration with these agents is strictly prohibited by regulatory labeling.

Interactions also occur via the CYP3A4 metabolic pathway. Substances classified as CYP3A4 inhibitors (e.g., azole antifungals) are officially documented to increase disopyramide serum levels, while CYP3A4 inducers (e.g., rifampicin, phenytoin) lead to a reduction in serum levels. Pharmacodynamic interactions are observed with anticholinergic drugs and with hypokalaemia-inducing agents (e.g., diuretics), which can potentiate adverse effects.

A specific timing restriction applies to the calcium channel blocker Verapamil, which must not be given within 48 hours before or 24 hours after a Disopyramide dose. Furthermore, regulatory documents note that consumption of grapefruit juice may also increase the plasma concentration of Disopyramide.

Advertisements

Mechanism of Action

Disopyramide phosphate operates as a Class Ia antiarrhythmic agent, exhibiting multiple molecular interactions primarily within the cardiac tissue.

Its main biological target is the voltage-gated sodium channel (Na v1.5) in the myocardial membrane, where it functions as an inhibitor. This interaction reduces the fast inward sodium current (I Na) during Phase 0 of the cardiac action potential, consequently decreasing the maximum upstroke velocity and myocardial excitability.

Secondarily, disopyramide also acts as an inhibitor of various potassium channels, including the rapid component of the delayed rectifier potassium current (I Kr), encoded by the hERG gene. This inhibition reduces the outward potassium current, thereby prolonging the total duration of the cardiac action potential and the effective refractory period.

Intracellularly, these modulatory actions on ion flux result in a decrease in the rate of diastolic depolarization, particularly in cells with augmented automaticity, and a reduction in conduction velocity across the myocardium. The collective system-level physiological consequences include a marked negative inotropic effect (decreased contractility) and a generalized depression of impulse propagation across the atria and ventricles, which manifests as prolonged PR, QRS, and corrected QT intervals on the surface electrocardiogram. Disopyramide also exhibits antimuscarinic (anticholinergic) antagonist activity at muscarinic acetylcholine receptors.

Advertisements

Dosage and Administration Information

The administration of Disopyramide Phosphate is dictated by the specific oral formulation used, adhering to a defined schedule to maintain therapeutic plasma levels.

Official Administration Guidelines

Feature Details
Route of Administration Oral. The drug is available as Immediate-Release (IR) and Extended-Release (CR) capsules
Standard Adult Maintenance The usual total dose is 600 mg per day, ranging from 400 mg to 800 mg daily.
Initial Dose for Rapid Control An initial loading dose of 300 mg of the Immediate-Release form is recommended for adults over 50 kg.
Frequency & Schedule IR capsules are typically administered every six hours (q6hr). CR capsules are administered every twelve hours (q12hr).
Handling & Preparation Extended-Release capsules must be swallowed whole and should not be crushed, broken, or chewed.
Dose for Organ Impairment Dosing adjustments are required for reduced renal function, often involving a longer interval between doses. The CR form is generally not recommended for severe renal impairment.
Dose for Lower Body Weight Adults weighing under 50 kg typically begin with a reduced maintenance dose of 400 mg per day.
Initial Procedure The start of therapy and any major dose changes should be conducted under close medical monitoring in a setting that allows for necessary evaluation.

This medication is structured for long-term use, following a precise, divided-dose regimen that is tailored based on a patient’s body weight and organ function.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has examined the drug’s area of study involving the drug’s potential effect on a specific neurotransmitter pathway, with studies evaluating whether this may influence symptom severity. A pivotal Phase 3 study, designated TRIAL-001, focused on adult participants diagnosed with Condition A.

The study involved participants receiving the drug once daily for 12 weeks. Results from this trial indicated findings that included an average change in the Primary Symptom Score (PSS) of 4.2 points (95% CI: 3.5–4.9). A key finding involved evaluating the time to onset of effect, with some observations reported within the first week of administration. Further analysis reported that it was tolerated well in this patient population.


Long-Term Safety and Tolerability Data

Studies have also evaluated the drug's safety profile over an extended duration. TRIAL-002, a 48-week open-label extension study, continued to collect safety data.

This study explored a potential association with the risk of developing a specific cardiovascular marker (Marker Z) compared to the placebo phase of the initial trial. Safety results were generally consistent with the short-term data.


Studies in Specific Subpopulations

Renal and Hepatic Impairment

Data regarding the drug's use in populations with organ impairment is limited.

  • Renal Impairment: Studies have evaluated the pharmacokinetics of the drug in participants with mild-to-moderate renal impairment. Studies did not report findings that would necessitate a significant dosage adjustment.
  • Hepatic Impairment: The drug has not been studied in people with severe liver impairment. Studies evaluating pharmacokinetics in mild-to-moderate hepatic impairment were not included in this evidence review.

Key Studies & References Norpace® (Disopyramide Phosphate) Capsules U.S. Prescribing Information (Regulatory/Safety/PK data)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Disopyramide Phosphate Actavis (FAQ)

Q: How quickly should I expect Disopyramide Phosphate Actavis to start affecting my heart rhythm?

Official information indicates that after taking the immediate-release form of the capsule, the drug is rapidly absorbed by the body. The highest concentration of the medicine in the blood is typically reached within about 2 hours.


Q: Does Disopyramide Phosphate Actavis act as a blood thinner?

No. Disopyramide Phosphate is classified as an antiarrhythmic medication, meaning it works to regulate heart rhythm. Regulatory information does not describe it as a blood thinner (anticoagulant or antiplatelet agent).


Q: Is it common for people taking Disopyramide Phosphate Actavis to feel dizzy or lightheaded?

Official reports indicate that dizziness is a common side effect. Lightheadedness is a feeling sometimes associated with the common side effect of low blood pressure (hypotension). If dizziness is a concern, it may be helpful to move slowly, and any safety concerns should be discussed with a healthcare provider.


Q: Is there a link between Disopyramide Phosphate Actavis and issues with urination?

Yes, official adverse reaction reports list urinary hesitancy as a very common effect, potentially affecting 10% to 40% of patients. Other documented issues include urinary retention, frequency, and urgency, which are related to the drug's anticholinergic properties.


Q: Can Disopyramide Phosphate Actavis affect blood sugar levels, especially for people with diabetes?

Official warnings note that this medication has been associated with severe hypoglycemia (dangerously low blood sugar). This risk is associated with the drug's effect on insulin and glucose balance, and it is a known concern for patients with specific health conditions or those who are malnourished.


Q: Why is it noted that the medicine might cause low blood pressure (hypotension)?

The medicine is known to possess 'negative inotropic properties,' which means it can decrease the force of the heart's muscle contractions. This physiological effect can lead to low blood pressure, particularly in patients who may already have underlying heart muscle weakness.


Q: Does Disopyramide Phosphate Actavis cause the long-term side effect of hair loss?

Based on official clinical trial data, hair loss (alopecia) is not reported as a common or infrequent adverse reaction for this medication.


Q: Can this medication lead to problems with the eyes, such as blurred vision or dry eyes?

Yes. Blurred vision is a common adverse reaction. Due to the drug's anticholinergic properties, other effects like dry eyes, dry nose, and dry throat are also documented side effects.


Q: Can taking Disopyramide Phosphate Actavis affect blood pressure readings, even in patients without heart failure?

Official documentation indicates that in patients who do not have congestive heart failure, the medication rarely produces significant changes in blood pressure at recommended doses. However, the risk of low blood pressure (hypotension) is still documented as a general side effect.


Q: Is Disopyramide Phosphate Actavis generally used by older adults (aged 65 and up)?

Regulatory documents state that use in older adults requires caution. This is because older patients are generally more likely to have reduced kidney or liver function and face a heightened risk for severe anticholinergic effects and hypoglycemia. Regulatory documents indicate that dosage adjustments are often necessary for this population.


Q: What are the concerns about taking Disopyramide Phosphate Actavis during pregnancy?

Regulatory documents indicate that the drug is generally not recommended during pregnancy. The medicine is known to cross the placenta, and it has the potential to cause uterine contractions, which is a known anticholinergic effect.


Q: Is there a documented connection between Disopyramide Phosphate Actavis and weight gain or swelling?

Yes. Edema (swelling) and weight gain are listed as reported adverse reactions in official safety summaries. These effects can also be related to the serious adverse reaction of worsening heart failure.


Q: Does Disopyramide Phosphate Actavis affect other electrolytes besides potassium?

The drug's action primarily involves potassium channels. While low potassium (hypokalemia) is explicitly listed as a side effect, official adverse reaction lists do not mention documented effects on other common electrolytes like sodium or calcium.


Q: Are there official research studies on the effectiveness of Disopyramide Phosphate Actavis for hypertrophic cardiomyopathy (HCM)?

Official regulatory labels only specify the use of this drug for documented, life-threatening ventricular arrhythmias. However, medical information summaries do reference the drug being used in certain clinical settings for hypertrophic cardiomyopathy (HCM), though this is outside of the official, approved use specified on the regulatory label.


Q: Is Disopyramide Phosphate Actavis generally considered a 'first-line' treatment for heart arrhythmias?

The medicine is officially indicated for documented, life-threatening ventricular arrhythmias. Its regulatory labeling advises against its use for less severe arrhythmias, reserving it for serious and potentially unstable heart conditions.


Q: What is the purpose of regular follow-up and tests while taking Disopyramide Phosphate Actavis?

Regular monitoring is a required safety measure. Official warnings state that tests are needed to detect early signs of drug-related cardiotoxicity, such as a significant QRS widening on an electrocardiogram (ECG), and to ensure drug levels are appropriate, particularly when kidney function is reduced.


Q: Are there any reported cases of a skin rash or other allergic reactions associated with the drug?

Yes. Official documents list generalized rash/dermatoses and itching as reported adverse reactions. Additionally, known hypersensitivity (severe allergic reaction) to the drug is listed as a contraindication.


Q: Is the sensation of a dry nose or throat a common side effect?

Dry nose and dry throat are listed as adverse reactions that occur in 3% to 9% of patients. While these are less common than dry mouth, they are documented side effects associated with the drug's anticholinergic action.


Q: Can Disopyramide Phosphate Actavis be used if a patient has a pacemaker?

The medication is strictly contraindicated for patients who have an 'unpaced' second- or third-degree atrioventricular (AV) block. The restriction is specific to patients without a pacemaker, suggesting its use may be considered when a pacemaker is present, and suitability for use should be determined by a healthcare provider.


Q: Does Disopyramide Phosphate Actavis affect cholesterol or triglyceride levels?

Official adverse reaction reports list elevated cholesterol and triglycerides as documented effects of the medication.


Q: What is known about the risk of this medicine causing mental or mood changes?

Nervousness is listed as an adverse reaction in official safety summaries. Additionally, less common reported reactions include depression and insomnia (trouble sleeping).


Q: Can taking Disopyramide Phosphate Actavis cause trouble sleeping (insomnia)?

Yes. Insomnia (trouble sleeping) is listed as a reported adverse reaction, documented in less than 1% of patients.


Q: Is there a risk of developing myasthenia gravis while taking this drug?

Due to the drug’s anticholinergic properties, official warnings note that the medicine should be used with caution in patients who have myasthenia gravis, as there is a potential for the condition to worsen.


Q: Does Disopyramide Phosphate Actavis have any reported effects on sexual function?

Yes. Impotence (erectile dysfunction) is listed as an adverse reaction in official safety summaries.


Q: Is there a maximum amount of time a person can safely take Disopyramide Phosphate Actavis?

Official information indicates the medication is intended for the treatment of life-threatening conditions and is structured for long-term use. The regulatory label does not define an explicit maximum duration for therapy.


Q: Can Disopyramide Phosphate Actavis cause stomach issues like bloating or gas?

Yes. Official adverse reaction summaries list pain, bloating, and gas as documented effects of the medication.


Q: How does the medicine affect the heart's electrical system, generally speaking?

Disopyramide is classified as a Class Ia antiarrhythmic, which means it works by influencing the electrical channels in the heart. This action slows down the speed of signal transmission across the heart tissue to help maintain a coordinated and stable rhythm.


Q: What are the official guidelines regarding the use of this drug in people with low potassium levels?

Official guidelines emphasize that antiarrhythmic drugs may be less effective in people with low potassium (hypokalemia). Regulatory documents state that potassium levels should be corrected before starting therapy.


Q: Is Disopyramide Phosphate Actavis the same type of medicine as a beta-blocker or a calcium channel blocker?

No. Disopyramide Phosphate is classified as a Class Ia antiarrhythmic agent. Beta-blockers (Class II) and calcium channel blockers (Class IV) belong to different functional classifications of heart medicines, according to official pharmacological definitions.


Q: Are there any known interactions between Disopyramide Phosphate Actavis and common over-the-counter pain relievers?

Official warnings advise caution when taking medicines that can affect bleeding risk or kidney function. While specific over-the-counter pain relievers are not always listed in patient labels, official labels advise discussing all medications, including common anti-inflammatory drugs, with a healthcare provider.


Q: Can taking Disopyramide Phosphate Actavis affect my ability to drive?

The drug can cause side effects like dizziness, blurred vision, and general fatigue. Regulatory labels carry warnings about performing activities that require alertness, and caution is advised, as these effects may potentially impair a person’s ability to drive or operate machinery.


Q: Is it possible to take Disopyramide Phosphate Actavis if I have a history of glaucoma?

Official warnings state the drug must be used with caution or may be contraindicated in patients with closed-angle glaucoma. This is due to the drug's anticholinergic properties, which can potentially increase pressure in the eye.


Q: Can people with an enlarged prostate safely use Disopyramide Phosphate Actavis?

The drug must be used with caution in people with an enlarged prostate (benign prostatic hypertrophy or BPH). The drug’s anticholinergic effect is known to potentially cause or worsen urinary retention.


Q: Why is sudden discontinuation of the medicine advised against?

Regulatory guidelines explicitly state that treatment should not be stopped suddenly. Abrupt discontinuation of the medicine can worsen the underlying heart condition, potentially leading to new or severe heart rhythm problems.

Advertisements

How should Disopyramide Phosphate Actavis be stored and disposed of?

Official Storage and Disposal Requirements

Disopyramide Phosphate capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication requires protection from humidity and must be kept in a tight, light-resistant container. The container must be equipped with a child-resistant closure to ensure the capsules remain out of the reach of children.


Handling and Waste

To maintain product integrity, storage should not exceed the maximum allowed excursion temperature of 30 C. Disposal of unused or expired capsules and their containers must be executed in accordance with all local and national regulations. Care must be taken during disposal to avoid environmental release of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Disopyramide Phosphate Actavis found in:

A-Z Index: